ArticleFrontiers in medicine2026
Real-world toxicity and discontinuation risk in ibrutinib therapy: a retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ibrutinib is widely used in B-cell malignancies, yet real-world safety data remain heterogeneous, particularly in underrepresented regional populations. Objective: To characterize the adverse-event profile and severity and explore factors associated with Grade 3-5 toxicity and permanent treatment discontinuation among patients receiving ibrutinib in routine clinical practice. Methods: A retrospective cohort study was conducted at King Abdullah Medical City, Makkah, Saudi Arabia, with follow-up through December 2025. Adult patients with B-cell malignancies who received ibrutinib and had sufficient clinical documentation for safety-outcome ascertainment were included. The primary endpoint was the occurrence of at least one Grade 3-5 adverse event according to CTCAE v5.0. Secondary outcomes included dose modifications, permanent treatment discontinuation, factors associated with toxicity, and temporal adverse-event patterns. Results: Among 57 patients, all 57 (100%) experienced at least one adverse event and 41 (71.9%) experienced at least one Grade 3-5 adverse event. Neutropenia and hypertension were the most frequent severe toxicities. Dose modification occurred in 47 patients (82.5%), and permanent discontinuation occurred in 17 (29.8%). In reduced Firth penalized-likelihood models adjusted for starting-dose category, pre-existing ischemic heart disease was associated with permanent discontinuation (aOR 6.25, 95% profile-likelihood CI 1.29-39.19; Conclusion: Ibrutinib was associated with substantial toxicity and frequent treatment modification in routine clinical practice. Pre-existing ischemic heart disease and impaired renal function emerged as exploratory markers of treatment vulnerability. The temporal findings support continued surveillance throughout therapy but do not establish a phase-specific monitoring strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.